Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer

Đang chuẩn bị liên kết để tải về tài liệu:
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer

Minh Kiệt 72 9 pdf

Non-muscle-invasive bladder cancer (NMIBC) is a high incidence form of bladder cancer (BCa), where genetic and epigenetic alterations occur frequently. We assessed the performance of associating a FGFR3 mutation assay and a DNA methylation analysis to improve bladder cancer detection and to predict disease recurrence of NMIBC patients. |

Đang chuẩn bị liên kết để tải về tài liệu:
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer

Meta-analysis: Assocation between promoter hypermethylation of dapk (death-associated Protein Kinase) and cervical cancer

Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: A case report and literature review

Hypermethylation at CpG islands of GSTP1 gene’s promoter is the typical property of breast cancer in Vietnamese population

In silico analysis of hypermethylation of E-cadherin gene promoter in nasopharyngeal carcinoma

The hypermethylation of p16 gene exon 1 and exon 2: Potential biomarkers for colorectal cancer and are associated with cancer pathological staging

Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China

Alcohol dehydrogenase, iron containing, 1 promoter hypermethylation associated with colorectal cancer differentiation

Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns

DNA hypermethylation patterns of APC gene promoter in Vietnamese high-risk HPV infected patients

RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas

Đang chuẩn bị liên kết để tải về tài liệu: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer

Meta-analysis: Assocation between promoter hypermethylation of dapk (death-associated Protein Kinase) and cervical cancer

Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: A case report and literature review

Hypermethylation at CpG islands of GSTP1 gene’s promoter is the typical property of breast cancer in Vietnamese population

In silico analysis of hypermethylation of E-cadherin gene promoter in nasopharyngeal carcinoma

The hypermethylation of p16 gene exon 1 and exon 2: Potential biomarkers for colorectal cancer and are associated with cancer pathological staging

Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China

Alcohol dehydrogenase, iron containing, 1 promoter hypermethylation associated with colorectal cancer differentiation

Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns

DNA hypermethylation patterns of APC gene promoter in Vietnamese high-risk HPV infected patients

RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas

Đang chuẩn bị liên kết để tải về tài liệu:
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer